Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The timing of auditory sensory deficits in Norrie disease has implications for therapeutic intervention
Dale Bryant, Valda Pauzuolyte, Neil J. Ingham, Aara Patel, Waheeda Pagarkar, Lucy A. Anderson, Katie E. Smith, Dale A. Moulding, Yeh C. Leong, Daniyal J. Jafree, David A. Long, Amina Al-Yassin, Karen P. Steel, Daniel J. Jagger, Andrew Forge, Wolfgang Berger, Jane C. Sowden, Maria Bitner-Glindzicz
Dale Bryant, Valda Pauzuolyte, Neil J. Ingham, Aara Patel, Waheeda Pagarkar, Lucy A. Anderson, Katie E. Smith, Dale A. Moulding, Yeh C. Leong, Daniyal J. Jafree, David A. Long, Amina Al-Yassin, Karen P. Steel, Daniel J. Jagger, Andrew Forge, Wolfgang Berger, Jane C. Sowden, Maria Bitner-Glindzicz
View: Text | PDF
Research Article Development Otology

The timing of auditory sensory deficits in Norrie disease has implications for therapeutic intervention

  • Text
  • PDF
Abstract

Norrie disease is caused by mutation of the NDP gene, presenting as congenital blindness followed by later onset of hearing loss. Protecting patients from hearing loss is critical for maintaining their quality of life. This study aimed to understand the onset of pathology in cochlear structure and function. By investigating patients and juvenile Ndp-mutant mice, we elucidated the sequence of onset of physiological changes (in auditory brainstem responses, distortion product otoacoustic emissions, endocochlear potential, blood-labyrinth barrier integrity) and determined the cellular, histological, and ultrastructural events leading to hearing loss. We found that cochlear vascular pathology occurs earlier than previously reported and precedes sensorineural hearing loss. The work defines a disease mechanism whereby early malformation of the cochlear microvasculature precedes loss of vessel integrity and decline of endocochlear potential, leading to hearing loss and hair cell death while sparing spiral ganglion cells. This provides essential information on events defining the optimal therapeutic window and indicates that early intervention is needed. In an era of advancing gene therapy and small-molecule technologies, this study establishes Ndp-mutant mice as a platform to test such interventions and has important implications for understanding the progression of hearing loss in Norrie disease.

Authors

Dale Bryant, Valda Pauzuolyte, Neil J. Ingham, Aara Patel, Waheeda Pagarkar, Lucy A. Anderson, Katie E. Smith, Dale A. Moulding, Yeh C. Leong, Daniyal J. Jafree, David A. Long, Amina Al-Yassin, Karen P. Steel, Daniel J. Jagger, Andrew Forge, Wolfgang Berger, Jane C. Sowden, Maria Bitner-Glindzicz

×

Figure 2

Early onset of hearing impairment in Ndp-KO mice.

Options: View larger image (or click on image) Download as PowerPoint
Early onset of hearing impairment in Ndp-KO mice.
ABR (A and B) and DPOA...
ABR (A and B) and DPOAE (C and D) thresholds and endocochlear potentials (EPs) (E and F) for individual animals were plotted as mean ± SD from WT mice (blue) and Ndp-KO mice (red) aged 1 month and 2 months. Ck, click. (A) No difference in ABR thresholds between genotypes at 1 month (Mann-Whitney rank sum test; U = 1050, T = 2226, P = 0.4540). (B) Ndp-KO mice show hearing loss in low frequencies at 2 months (U = 2754.4, T = 5382.5, P = 0.0026). n = 11 WT, n = 12 Ndp-KO at 1 month; n = 9 WT, n = 13 Ndp-KO at 2 months. (C and D) DPOAEs were comparable between genotypes at 1 month (U = 1252.5, T = 2527.5, P = 0.1326). At 2 months, Ndp-KO thresholds increased over all frequencies compared with controls (U = 689.5, T = 1724.5, P < 0.00000001). n = 10 WT, n = 12 Ndp-KO at 1 month; n = 9 WT, n = 13 Ndp-KO at 2 months. (E) At 1 month, EP was significantly lower in Ndp-KO than in WT, but within normal range (>100 mV); n = 11 WT, n = 12 Ndp-KO. (F) At 2 months, Ndp-KO EP decreased further; n = 7 WT, n = 12 Ndp-KO (2-way ANOVA; significant effect of age, F = 4.3400, P = 0.0440; significant effect of genotype, F = 29.9970, P = 0.0000297). There was a significant reduction at 1 month (E) (Holm-Šidák method for multiple comparisons; t = 3.5946, P = 0.00092067) and at 2 months (F) (Holm-Šidák method for multiple comparisons; t = 4.1323, P = 0.00019031). n = 11 WT, n = 12 Ndp-KO at 1 month; n = 7 WT, n = 12 Ndp-KO at 2 months.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts